Fusion Pharmaceuticals FUSN Stock
Fusion Pharmaceuticals Price Chart
Fusion Pharmaceuticals FUSN Financial and Trading Overview
| Fusion Pharmaceuticals stock price | 21.41 USD |
| Previous Close | 4.64 USD |
| Open | 4.71 USD |
| Bid | 0 USD x 1100 |
| Ask | 0 USD x 4000 |
| Day's Range | 4.63 - 4.8 USD |
| 52 Week Range | 1.98 - 5.63 USD |
| Volume | 16.48K USD |
| Avg. Volume | 68.71K USD |
| Market Cap | 296.25M USD |
| Beta (5Y Monthly) | -1.171042 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.78 USD |
FUSN Valuation Measures
| Enterprise Value | 136.47M USD |
| Trailing P/E | N/A |
| Forward P/E | -2.7619047 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 327.70514 |
| Price/Book (mrq) | 1.4600377 |
| Enterprise Value/Revenue | 150.958 |
| Enterprise Value/EBITDA | -1.493 |
Trading Information
Fusion Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | -1.171042 |
| 52-Week Change | 42.76% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 5.63 USD |
| 52 Week Low | 1.98 USD |
| 50-Day Moving Average | 4.32 USD |
| 200-Day Moving Average | 3.45 USD |
FUSN Share Statistics
| Avg. Volume (3 month) | 68.71K USD |
| Avg. Daily Volume (10-Days) | 50.65K USD |
| Shares Outstanding | 63.85M |
| Float | 46.62M |
| Short Ratio | 7.52 |
| % Held by Insiders | 5.90% |
| % Held by Institutions | 59.97% |
| Shares Short | 241.93K |
| Short % of Float | 0.41% |
| Short % of Shares Outstanding | 0.38% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -10217.25% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -22.97% |
| Return on Equity (ttm) | -44.20% |
Income Statement
| Revenue (ttm) | 904K USD |
| Revenue Per Share (ttm) | 0.02 USD |
| Quarterly Revenue Growth (yoy) | -95.19% |
| Gross Profit (ttm) | -57434000 USD |
| EBITDA | -91385000 USD |
| Net Income Avi to Common (ttm) | -91994000 USD |
| Diluted EPS (ttm) | -1.87 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 209.84M USD |
| Total Cash Per Share (mrq) | 3.29 USD |
| Total Debt (mrq) | 50.07M USD |
| Total Debt/Equity (mrq) | 24.93 USD |
| Current Ratio (mrq) | 12.734 |
| Book Value Per Share (mrq) | 3.178 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -83740000 USD |
| Levered Free Cash Flow (ttm) | -50924500 USD |
Profile of Fusion Pharmaceuticals
| Country | United States |
| State | ON |
| City | Hamilton |
| Address | 270 Longwood Road South |
| ZIP | L8P 0A6 |
| Phone | 289 799 0891 |
| Website | https://fusionpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 106 |
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. Its lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it develops FPI-1966 for the treatment of multiple cancers, including colorectal, ovarian, bladder, and head and neck cancers. The company has a strategic collaboration agreement with AstraZeneca UK Limited to discover, develop, and commercialize alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. Fusion Pharmaceuticals Inc. was incorporated in 2014 and is headquartered in Hamilton, Canada.
Q&A For Fusion Pharmaceuticals Stock
What is a current FUSN stock price?
Fusion Pharmaceuticals FUSN stock price today per share is 21.41 USD.
How to purchase Fusion Pharmaceuticals stock?
You can buy FUSN shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Fusion Pharmaceuticals?
The stock symbol or ticker of Fusion Pharmaceuticals is FUSN.
Which industry does the Fusion Pharmaceuticals company belong to?
The Fusion Pharmaceuticals industry is Biotechnology.
How many shares does Fusion Pharmaceuticals have in circulation?
The max supply of Fusion Pharmaceuticals shares is 85.06M.
What is Fusion Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Fusion Pharmaceuticals PE Ratio is 0.00000000 now.
What was Fusion Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Fusion Pharmaceuticals EPS is 0 USD over the trailing 12 months.
Which sector does the Fusion Pharmaceuticals company belong to?
The Fusion Pharmaceuticals sector is Healthcare.
Fusion Pharmaceuticals FUSN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17382.94 USD — |
+1.26
|
6.5B USD — | 17110.72 USD — | 17404.49 USD — | — - | 6.5B USD — |
| NASDAQ Global Select Market Com NQGS | 8504.39 USD — |
+1.34
|
— — | 8367.19 USD — | 8515.13 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 923.51 USD — |
-0.73
|
— — | 917.75 USD — | 925.61 USD — | — - | — — |
- {{ link.label }} {{link}}